MedTrace Logo

Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections

NCT00870623 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 223

Last updated 2023-09-15

No results posted yet for this study

Summary

Bloodstream infections (BSI) are a major cause of morbidity and mortality. Bloodstream infections are also costly and result in prolonged hospital stays. The duration of therapy necessary to clear blood stream infections is unknown and no study has systematically addressed this issue. However, the use of antimicrobials is not without consequence. These include financial cost, side-effects, promotion of superinfection (especially Clostridium difficile-associated diarrhea), and the promotion of microbial resistance. This study hypothesizes that a procalcitonin (host biomarker) and endotoxin (microorganism biomarker) guided treatment plan could significantly decrease unnecessary exposure to antibiotics in patients with bloodstream infections.

Conditions

  • Bloodstream Infection

Sponsors & Collaborators

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Andre Kalil, MD · University of Nebraska

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-01
Primary Completion
2016-01-13
Completion
2016-01-13

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00870623 on ClinicalTrials.gov